Research & Development

GlaxoSmithKline plc and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis…
Axion BioSystems, the global leader in microelectrode array (MEA) technology, introduces the next generation of MEA platforms, Maestro Pro and Maestro Edge.Excitable cells play a fundamental role in life, from heart beats to brain function. Maestro MEA systems capture live-cell activity from electroactive cells in real-time, allowing scientists to recreate…
Belgium-based CDMO Kaneka Eurogentec, a unit of Japanese chemical giant Kaneka, will build a new biologics manufacturing facility as part of the company’s expansion into large-scale production of biopharmaceuticals. Construction is expected to begin in the coming months at a site located near Eurogentec’s current production facility in Seraing, Belgium.…
NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug Administration for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin enrolling patients in a…
Jazz Pharmaceuticals plc and ImmunoGen, Inc. announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as an additional program to be designated during the term…
Page 1 of 30

Subscribe To Our Newsletter

Security Q:How many eyes has a typical person? (ex: 1)
Name:
Email: